Blueprint Medicines Corp. is a biopharmaceutical company focused on developing targeted therapies to treat genomically defined cancers, rare diseases, and cancer immunotherapy. The company's primary purpose is to utilize its proprietary scientific platform to develop medicines that inhibit the protein kinases that drive the growth of specific diseases. Blueprint Medicines’ pipeline includes a variety of drug candidates that address significant unmet medical needs within oncology and hematology sectors. Notably, it impacts areas such as systemic mastocytosis, gastrointestinal stromal tumors, and advanced or metastatic thyroid cancers. Blueprint Medicines plays a crucial role in the financial market by offering innovative solutions in precision therapy, attracting investment interest in the healthcare and biotechnology sectors. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company leverages genomics and data science to advance its mission of delivering transformative treatments for patients around the world.